Researchers sought to characterize the prevalence and clinical features of individuals with both MS and INO in a population-based cohort of patients with MS.
Researchers sought to assess the change in blood pressure in patients with MS treated with ATZ and prior HDMP treatment compared with patients receiving HDMP only for acute relapse.
In a prospective cohort study, researchers assessed whether adverse childhood experiences may increase the risk for multiple sclerosis in women.
For individuals with MS and cancer, breast cancers are less likely to be detected through screening and colorectal cancer is more likely to be detected at an early stage.
The prevalence of multiple sclerosis (MS) is similarly high in Black and White individuals and is lower in Hispanics and Asians.
The total economic burden of multiple sclerosis (MS) in the United States in 2019 was $85.4 billion, including $63.3 billion in direct medical costs.
Childhood sexual and emotional abuse are associated with an increased risk for developing multiple sclerosis (MS) in women.
Using data from the Ultimate I and II phase 3 trials, researchers conducted a post-hoc analysis to study the effects of ublituximab on disease activity in relapsing multiple sclerosis.
Presenting at the 2022 AAN Annual Meeting, researchers assessed the neuropsychological profile of pediatric MS and its association with resting-state functional connectivity abnormalities in cognitive and motor networks.
Presenting at the 2022 AAN Annual Meeting, researchers evaluated a case of 48-year-old woman who developed atypical optic neuritis induced by golimuab treatment.